Equities
Health CareMedical Equipment and Services
  • Price (USD)513.26
  • Today's Change-2.84 / -0.55%
  • Shares traded1.83m
  • 1 Year change+5.28%
  • Beta0.7731
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy8
Outperform18
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 27 analysts offering 12 month price targets for Thermo Fisher Scientific Inc have a median target of 655.00, with a high estimate of 767.00 and a low estimate of 585.20. The median estimate represents a 26.91% increase from the last price of 516.10.
High48.6%767.00
Med26.9%655.00
Low13.4%585.20

Dividends in USD

In 2023, Thermo Fisher Scientific Inc reported a dividend of 1.35 USD, which represents a 16.38% increase over last year. The 13 analysts covering the company expect dividends of 1.54 USD for the upcoming fiscal year, an increase of 13.70%.
Div growth (TTM)16.38%
More ▼

Earnings history & estimates in USD

On Oct 23, 2024, Thermo Fisher Scientific Inc reported 3rd quarter 2024 earnings of 5.28 per share. This result was in line with the consensus of the 23 analysts following the company and under-performed last year's 3rd quarter results by 7.21%.
The next earnings announcement is expected on Jan 31, 2025.
Average growth rate-1.70%
Thermo Fisher Scientific Inc reported annual 2023 earnings of 21.55 per share on Jan 31, 2024.
Average growth rate+18.01%
More ▼

Revenue history & estimates in USD

Thermo Fisher Scientific Inc. had 3rd quarter 2024 revenues of 10.60bn. This missed the 10.64bn consensus estimate of the 21 analysts following the company. This was 1.05% below the prior year's 3rd quarter results.
Average growth rate+0.10%
Thermo Fisher Scientific Inc. had revenues for the full year 2023 of 42.86bn. This was 4.58% below the prior year's results.
Average growth rate+14.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.